Yoshiaki Furukawa Selected Research

Dopa-responsive Dystonia

1/2020	Comment on "Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?"
5/2015	Parkinsonism in GTP cyclohydrolase 1-deficient DOPA-responsive dystonia.
11/2006	[Dopa-responsive dystonia].
1/2006	[Dopa-responsive dystonia: clinical, genetic, and biochemical studies].
7/2003	VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET.
1/2003	Genetics and biochemistry of dopa-responsive dystonia: significance of striatal tyrosine hydroxylase protein loss.
5/2002	Brain biopterin and tyrosine hydroxylase in asymptomatic dopa-responsive dystonia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoshiaki Furukawa Research Topics

Disease

29	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2022 - 04/2005
16	Parkinson Disease (Parkinson's Disease) 01/2022 - 06/2002
14	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 01/2003
10	Multiple System Atrophy 01/2022 - 06/2002
7	Dopa-responsive Dystonia 01/2020 - 05/2002
5	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 09/2017 - 09/2003
4	Gliosis 01/2020 - 07/2014
4	Parkinsonian Disorders (Parkinsonism) 09/2017 - 06/2002
4	Dyskinesias (Dyskinesia) 01/2016 - 01/2004
4	Huntington Disease (Huntington's Disease) 10/2012 - 03/2008
3	Synucleinopathies 01/2022 - 01/2010
3	Dementia (Dementias) 01/2022 - 01/2010
3	Cognitive Dysfunction 01/2022 - 01/2008
3	Dystonia (Limb Dystonia) 01/2021 - 10/2004
2	Dystonic Disorders (Writer's Cramp) 11/2006 - 01/2006
1	Spinal Cord Diseases 01/2022
1	Substance-Related Disorders (Drug Abuse) 09/2020
1	Cocaine-Related Disorders (Cocaine Addiction) 01/2018
1	Heroin Dependence (Heroin Abuse) 01/2018
1	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 04/2017
1	Motor Neuron Disease (Primary Lateral Sclerosis) 04/2017
1	Proteostasis Deficiencies 04/2017
1	Substance Withdrawal Syndrome (Withdrawal Symptoms) 03/2016
1	Disruptive, Impulse Control, and Conduct Disorders (Kleptomania) 02/2015
1	Glucose Intolerance 01/2015
1	Type 2 Diabetes Mellitus (MODY) 01/2015
1	Ischemic Stroke 01/2015
1	Stroke (Strokes) 01/2015
1	Prediabetic State (Prediabetes) 01/2015
1	Transient Ischemic Attack 01/2015
1	Takotsubo Cardiomyopathy 06/2014
1	Bipolar Disorder (Manic Depressive Psychosis) 06/2014
1	Opsoclonus-Myoclonus Syndrome (Kinsbourne Syndrome) 05/2013
1	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 12/2011
1	Tauopathies 08/2011
1	Muscle Cramp (Cramp) 02/2011
1	Hyperthermia 06/2010

Drug/Important Bio-Agent (IBA)

26	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2002
23	Superoxide Dismutase-1IBA 01/2020 - 04/2005
11	Dopamine (Intropin)FDA LinkGeneric 01/2021 - 05/2002
6	Levodopa (L Dopa)FDA LinkGeneric 01/2016 - 01/2004
5	EnzymesIBA 09/2020 - 01/2003
5	Pharmaceutical PreparationsIBA 09/2017 - 01/2008
3	alpha-SynucleinIBA 01/2022 - 01/2010
3	Serotonin (5 Hydroxytryptamine)IBA 01/2021 - 01/2008
3	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 01/2020 - 05/2002
3	RNA-Binding Proteins (RNA-Binding Protein)IBA 04/2017 - 03/2008
3	Methamphetamine (Desoxyn)FDA LinkGeneric 03/2016 - 06/2010
3	Dopamine Receptors (Dopamine Receptor)IBA 01/2016 - 05/2009
3	polyglutamineIBA 06/2010 - 03/2008
2	PrionsIBA 01/2022 - 01/2019
2	AntibodiesIBA 11/2019 - 05/2013
2	AntioxidantsIBA 01/2018 - 09/2003
2	CopperIBA 01/2018 - 04/2016
2	Superoxide DismutaseIBA 01/2018 - 02/2013
2	Glutathione (Reduced Glutathione)IBA 01/2018 - 09/2003
2	naxagolideIBA 01/2016 - 05/2009
2	Dopamine Agonists (Dopamine Agonist)IBA 02/2015 - 02/2003
2	DisulfidesIBA 02/2013 - 05/2006
2	BiopterinsIBA 01/2006 - 05/2002
2	Peptide Hydrolases (Proteases)FDA Link 01/2003 - 06/2002
2	UbiquitinIBA 01/2003 - 06/2002
2	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2003 - 06/2002
1	2-oxindole (oxindole)IBA 01/2022
1	Amyloidogenic ProteinsIBA 01/2022
1	sepiapterin reductaseIBA 01/2021
1	TensinsIBA 01/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2021
1	Tryptophan (L-Tryptophan)FDA Link 09/2020
1	Acetylcysteine (Siran)FDA LinkGeneric 01/2018
1	DNA-Binding Proteins (DNA Binding Protein)IBA 01/2018
1	ZincIBA 01/2018
1	Cocaine (Cocaine HCl)IBA 01/2018
1	Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)IBA 09/2017
1	Monoamine Oxidase (MAO)IBA 09/2017
1	Oxidoreductases (Dehydrogenase)IBA 09/2017
1	RNA (Ribonucleic Acid)IBA 04/2017
1	dihydrotetrabenazineIBA 03/2016
1	SolutionsIBA 02/2016
1	SynucleinsIBA 10/2015
1	Cysteine (L-Cysteine)FDA Link 08/2015
1	GTP Cyclohydrolase (GTP Cyclohydrolase I)IBA 05/2015
1	PPAR-gamma AgonistsIBA 01/2015
1	Pioglitazone (Actos)FDA Link 01/2015
1	Glucose (Dextrose)FDA LinkGeneric 01/2015
1	HLA-DR Antigens (HLA-DR)IBA 07/2014
1	HLA Antigens (Human Leukocyte Antigens)IBA 07/2014
1	Glial Fibrillary Acidic ProteinIBA 07/2014
1	VimentinIBA 07/2014
1	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 07/2014
1	HSP27 Heat-Shock ProteinsIBA 07/2014
1	LithiumIBA 06/2014
1	Methionine (L-Methionine)FDA Link 10/2012
1	DNA (Deoxyribonucleic Acid)IBA 12/2011
1	Carrier Proteins (Binding Protein)IBA 08/2011
1	Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)IBA 02/2011
1	polysialyl neural cell adhesion moleculeIBA 02/2011
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 02/2011

Therapy/Procedure

3	Therapeutics 10/2015 - 10/2004